Clinical Trial

A Study of SPY072 in Rheumatic Disease

Study acronym: SKYWAY-RD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-06
notable Trial sites expanded: 57 -> 63 locations 2026-05-07
notable Trial sites expanded: 41 -> 57 locations 2026-04-23
Trial Details
NCT Number NCT07148414
Lead Sponsor Spyre Therapeutics, Inc.
Conditions Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Enrollment 285 participants
Start Date 2025-08-21
Primary Completion 2026-10-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-05